Last Updated:
Create account to add to watchlist!

Viveon Health Acquisition Corp. - VHAQ

  • Commons



    VHAQ Vol: 115.0

  • Warrants



    VHAQ+ Vol: 20.1K

  • Units



    VHAQ= Vol: 999.0

Average: 0
Rating Count: 0
You Rated: Not rated

Please log in to rate.

SPAC Stats

Market Cap: 252.1M
Average Volume: 11.2K
52W Range: $9.51 - $10.50
Weekly %: -0.10%
Monthly %: +0.10%
Inst Owners: 45


Target: Searching
Days Since IPO: 340
Unit composition:
Each unit consists of one share of common stock, par value $0.0001, one warrant, and one right to receive one-twentieth (1/20) of a share of common stock upon the consummation of an initial business combination, as described in more detail in this prospectus
Trust Size: 17000000.0M

🕵Stocktwit Mentions

T8skmod posted at 2021-11-23T05:11:37Z

$VHAQ - Twitter Latest Twits 🚀 : 29% 🚀

Tickstocks posted at 2021-11-22T19:07:37Z

$VHAQ Twits Stats Today's Change 7% + 🚀

Tickstocks posted at 2021-11-21T03:37:30Z

$VHAQ - Twitter Latest Twits 🚀 : 29% 🚀

OJGogo posted at 2021-11-17T23:36:02Z

$VHAQ Can't be too long for DA now. Right Bashley?

cctranscripts posted at 2021-11-17T22:27:13Z

Viveon Health Acquisition Corp. Just Filed Its Quarterly Report: Net Income Per Commo... $VHAQ

Last10K posted at 2021-11-17T22:26:51Z

$VHAQ just filed a 10-Q Quarterly Report with 40 sections and 4 exhibits. Access them all or just read their earnings:

risenhoover posted at 2021-11-17T22:24:36Z

$VHAQ / Viveon Health Acquisition files form 10-Q

Quantisnow posted at 2021-11-17T22:24:12Z

$VHAQ 📜 SEC Form 10-Q filed by Viveon Health Acquisition Corp. 45 seconds delayed.

fla posted at 2021-11-17T22:23:48Z

$VHAQ [15s. delayed] filed form 10-Q on November 17, 17:22:04

Newsfilter posted at 2021-11-17T22:23:21Z

$VHAQ Form 10-Q (quarterly report [sections 13 or 15(d)]) filed with the SEC

WarrenGShirley posted at 2021-11-17T19:45:17Z

$VHAQ rights on a riiiiiiippppp!!!!

_TheIronSheik_ posted at 2021-11-17T16:03:05Z

$VHAQ I have conferred with my camels; shorts will get the camel clutch here any day now! Load up all the warrants you can habibis 🌙 Salam Alaikum

T8skmod posted at 2021-11-17T10:02:19Z

$VHAQ Twits Stats Today's Change 7% + 🚀

AshleySchaeffer_BMW posted at 2021-11-17T00:19:18Z

$VHAQ ask yourself why bother to do all this paperwork if deal wasnt quickly approaching, load this up up with both hands tomorrow folks!!

risenhoover posted at 2021-11-16T23:55:07Z

$VHAQ / Viveon Health Acquisition files form 8-K - United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 15, 2021 Date of Report (Date of earliest event reported) Viveon Health Ac

cctranscripts posted at 2021-11-16T21:52:27Z

In connection with the preparation of the financialstatements of Viveon Health Acquisition $VHAQ

Last10K posted at 2021-11-16T21:51:16Z

$VHAQ just filed with the SEC a Interim Review

Quantisnow posted at 2021-11-16T21:50:39Z

$VHAQ 📜 Viveon Health Acquisition Corp. filed SEC Form 8-K: Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review 45 seconds delayed.

Newsfilter posted at 2021-11-16T21:49:49Z

$VHAQ Form 8-K: Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review. In connection with the preparation of the financial statements of Viveon H..

AshleySchaeffer_BMW posted at 2021-11-16T03:29:18Z

$VHAQ strong volume on warrants today, 🌚 soon 🔜

Tickstocks posted at 2021-11-16T01:17:00Z

$VHAQ - Twitter Latest Twits 🚀 : 29% 🚀

OJGogo posted at 2021-11-15T23:00:44Z

$VHAQ Yet another inability filling. DA must be around the corner, so they're busy. Right Bashley?

Newsfilter posted at 2021-11-15T21:41:02Z

$VHAQ Form NT 10-Q (notification of inability to timely file form 10-q or 10-qsb) filed with the SEC

Quantisnow posted at 2021-11-15T21:39:38Z

$VHAQ 📜 SEC Form NT 10-Q filed by Viveon Health Acquisition Corp. 45 seconds delayed.

risenhoover posted at 2021-11-15T21:39:06Z

$VHAQ / Viveon Health Acquisition files form NT 10-Q

T8skmod posted at 2021-11-14T08:23:57Z

$VHAQ - Twitte$ALSK Twits Stats Today's Change 29% + 🚀 Latest Twits 🚀 : 29% 🚀

T8skmod posted at 2021-11-14T08:13:54Z

$VHAQ - Twitter Latest Twits 🚀 : 29% 🚀

Tickstocks posted at 2021-11-12T05:45:18Z

$VHAQ - Twitter Latest Twits 🚀 : 29% 🚀

WarrenGShirley posted at 2021-11-11T15:39:09Z

$VHAQ rights getting slapped with low volume, either desperation or no sellers

Tickstocks posted at 2021-11-07T23:11:28Z

$VHAQ - Twitter Latest Twits 🚀 : 29% 🚀


Our current directors and executive officers are as follows: Name Age Position Jagi Gill 55 Chief Executive Officer and President Rom Papadopoulos 61 Chief Financial Officer, Treasurer and Secretary Lishan Aklog 55 Independent Director Brian Cole 58 Independent Director Doug Craft 58 Independent Director Jagi Gill, PhD, has served as our Chief Executive Officer since August 2010. Dr. Gill, has more than 20 years of healthcare investment and general management experience. From 2017 to 2020, he served as the Vice-President of Business Development and General Manager of AcuVentures, a business unit within Acumed LLC, a Berkshire Hathaway Company. Acumed LLC is a market leader in the orthopedic sector with particular strength in the upper extremity fracture repair and trauma market segments. As the General Manager, Dr. Gill led two business units, Rib Fixation and the Soft Tissue Repair, with responsibilities for product development, sales, marketing and profitability. Under his leadership, the business units grew 2-3x faster than their market segment. In addition to general management responsibilities, Dr. Gill was involved in sourcing, closing and integrating four acquisitions within the orthopedic sector for Acumed. These transactions ranged from technology acquisitions serving as tuck-in product integrations to stand alone companies with global revenue. From 2009 to 2017, he was the Founder, Chief Executive Officer and Board Member of Tenex Health a privately held orthopedic sports medicine company. In this capacity he patented, designed and developed the initial platform technology intended to treat chronic tendon pain. Under his leadership, Tenex Health launched commercially, generated positive operating income, secured FDA regulatory approval, developed a manufacturing and operations infrastructure, and established sales channels serving the outpatient Ambulatory Surgery Centers. Before founding Tenex Health, Dr. Gill was the Founder and Chief Executive Officer of OrthoCor, a company providing non-invasive pain management technology, from 2007 to 2009, while also serving on an advisory and consulting capacity to a number of medical technology companies. OrthoCor developed and commercialized orthopedic knee braces integrating pulsed electromagnetic technology to address chronic pain associated with trauma or osteoarthritis. Prior to this, he served in executive business development roles for Boston Scientific Corporation from 2001 to 2007 where he was involved in sourcing and supporting the acquisition of private companies which collectively accounted for more than $750 million in enterprise value. While at Boston Scientific, he was involved in the investments in, and acquisition of, the following private companies: Advanced Bionics (implantable neurostimulation), Cameron Health (implantable cardiac rhythm management), Innercool (systemic hypothermia for recovery from cardiac arrest), Orqis Medical (heart failure treatment) and Kerberos (endovascular thrombectomy). Dr. Gill completed his BSc and MSc in Anatomy from McGill University and PhD in Neuroscience from Mayo Clinic College of Medicine. We believe we will be able to capitalize on Dr. Gill’s experience and accomplishments in the orthopedic and spine markets, along with his relationships among executives in the target companies, their supply chains, and their customer networks, to successfully close a business combination. Rom Papadopoulos, M.D., has served as our Chief Financial Officer since August 2020. Dr. Papadopoulos has more than 25 years of healthcare investment and operational experience. From 2006 to June 2020, Dr. Papadopoulos was the Founder and Managing Partner of Intuitus Capital, a private equity firm actively investing in the healthcare sector. At Intuitus, he led investments in more than 30 companies with a total of more than $700 million in enterprise value. Prior to founding Intuitus Capital, Dr. Papadopoulos was Chief Financial Officer, Chief Operations Officer, Corporate Executive Vice President and Corporate Secretary of Global Energy Holdings (NYSE Amex: GNH). While at GNH, he created and executed the company’s repositioning from traditional markets to renewable energy. He was responsible for coordinating all aspects of the financial management of the company including cash management and treasury, risk management, audit functions, SEC reporting and compliance as well as HR functions and employee policies. Dr. Papadopoulos was an early investor in Tenex Health Inc., a medical device company engaged in the manufacturing and sale of minimally invasive high frequency technology used to perform percutaneous tenotomy and fasciotomy. He eventually became the interim CFO for the company until September 2013. In this capacity, he was an integral part of the team seeking and completing acquisitions for the company. From 2002 to 2006, Dr. Papadopoulos was the Managing Director and head of healthcare investment banking for Caymus Partners, a middle market investment banking firm. Dr. Papadopoulos received his medical degree (M.D.) from the Aristotelian University of Thessaloniki, 71 Table of Contents Greece, Medical School in 1985 and conducted his post-graduate training in Pediatrics at Emory University in 1986. We believe that Dr. Papadopoulos is qualified to sit on our board due to his years of experience in the healthcare industry, as a clinician as well as an investor who possesses unique insight into medical technology assets, in addition to his strong financial credentials. Lishan Aklog, MD is Co-Founder, Chairman and Chief Executive Officer of PAVmed Inc. Dr. Aklog has also served as Executive Chairman of Lucid Diagnostics Inc. since its inception in 2018, as a co-founding Partner of both Pavilion Holdings Group LLC (“PHG”), a medical device holding company, since its inception in 2007, and Pavilion Medical Innovations LLC, a venture-backed medical device incubator, since its inception in 2009. He previously served as Chairman and Chief Technology Officer of Vortex Medical Inc., a PHG portfolio company, from its inception in 2008 until its acquisition in October 2012 by Angiodynamics. and has served as a consultant and on the advisory boards of many major medical device companies as well as innovative startups. Dr. Aklog is an inventor on 25 issued patents and over 45 patent applications, including the core patents of Vortex Medical’s AngioVac® system and the patents for a majority of PAVmed Inc.’s products. Prior to entering the medical device industry full-time in 2012, Dr. Aklog was an academic cardiac surgeon serving, from 2006 to 2012, Associate Professor of Surgery, Chief of Cardiovascular Surgery and Chair of The Cardiovascular Center at St. Joseph’s Hospital and Medical Center’s Heart and Lung Institute in Phoenix, Arizona, from 2002 to 2006, as Assistant Professor of Cardiothoracic Surgery, Associate Chief of Cardiac Surgery and Director of Minimally Invasive Cardiac Surgery at Mount Sinai Medical Center in New York, and as Assistant Professor of Surgery at Harvard Medical School, Director of the Cardiac Surgery Research Laboratory, and an attending cardiac surgeon at Brigham and Women’s Hospital in Boston, from 1999 to 2002. Dr. Aklog received his clinical training in general and cardiothoracic surgery at Brigham and Women’s Hospital and Boston Children’s Hospital, during which he spent two years as the Medtronic Research Fellow at Harvard Medical School’s Cardiac Surgery Research Laboratory. He was then awarded the American Association of Thoracic Surgery Traveling Fellowship pursuant to which he received advanced training in heart valve surgery under renowned cardiac surgeons Sir Magdi Yacoub at Harefield Hospital in London and Professor Alain Carpentier at L’Hopital Broussais in Paris. Dr. Aklog is a co-author on 38 peer-reviewed articles and 10 book chapters. He has served on the Editorial Board of the Journal of Cardiothoracic Surgery since 2006. He is a member of numerous professional societies and has been elected to the American Association of Thoracic Surgery. He served on the Board of Directors of the International Society for Minimally Invasive Cardiothoracic Surgery from 2006 to 2009 and as President of the 21st Century Cardiothoracic Surgery Society in 2011. During his clinical career he was recognized as one of America’s Top Doctors in the Castle Connolly Guide from 2002 to 2013. He serves as Chairman of the Boston ECG Project Charitable Foundation and the International Board of Directors of Human Rights Watch. Dr. Aklog received his A.B., magna cum laude, in Physics from Harvard University, where he was elected to Phi Beta Kappa. Dr. Aklog received his M.D., cum laude, from Harvard Medical School. Brian Cole MD, MBA is the Managing Partner of Midwest Orthopedics at Rush in Chicago, the lead executive for this large specialty practice which is consistently ranked as one of the top orthopedic groups by US News & World Report. Dr. Cole is a Professor in the Department of Orthopedics with a conjoint appointment in the Department of Anatomy and Cell Biology at Rush University Medical Center. In 2015, he was appointed as an Associate-Chairman of the Department of Orthopedics at Rush. In 2011, he was appointed as Chairman of Surgery at Rush Oak Park Hospital. He is the Section Head of the Cartilage Research and Restoration Center at Rush specializing in the treatment of arthritis in young active patients with a focus on regenerative medicine and biologic alternatives to surgery. He also serves as the head of the Orthopedic Master’s Training Program and trains residents and fellows in sports medicine and research. He lectures nationally and internationally and holds several leadership positions in prominent sports medicine societies. Through his basic science and clinical research, he has developed several innovative techniques with several patents for the treatment of shoulder, elbow and knee conditions. He has published more than 1,000 articles and 10 widely read textbooks in orthopedics and regenerative medicine. In addition to his academic accomplishments, Dr. Cole currently serves in many senior leadership roles in organizations such as President of the Arthroscopy Association of North America, President of the Ortho-regeneration Network Foundation, and Secretary General (Presidential-line) International Cartilage Repair Society. Dr. Cole is frequently chosen as one of the “Best Doctors in America” since 2004 and as a “Top Doctor” in the Chicago metro area since 2003. In 2006, he was featured on the cover of Chicago Magazine as “Chicago’s Top Doctor” and was selected as NBA Team Physician of the Year in 2009. Orthopedics This Week has named Dr. Cole as one of the top 20 sports medicine, knee and shoulder specialists repeatedly over the last 5 years as selected by his peers. He is the head team physician for the Chicago Bulls NBA team, co-team physician for the Chicago White Sox MLB team and DePaul University in Chicago. Dr. Cole was awarded his medical degree from the University of Chicago Pritzker School of Medicine and his MBA from the University of Chicago Booth School of Business. He completed his residency in Orthopedic Surgery at the Hospital for Special Surgery — Cornell Medical Center in New York and his fellowship in Sports Medicine at the University of Pittsburgh. 72 Table of Contents Doug Craft is the Chief Executive Officer of Atlanta-based Medicraft, Inc., which is one of the largest independent agents for Medtronic, the world leader in medical technology and pioneering therapies. He has devoted his entire career to the medical industry, initially concentrating in the sale of spinal implants, which he continues today. Mr. Craft has extensive relationships with health care systems, surgeons and other senior health care professionals across the nation. Over the past three decades his commercial interests have expanded to include evaluating, consulting and developing businesses in the medical field generally, including but not limited to neuro-intraoperative monitoring, biologic agents, orthopedic reconstruction implants, surgical navigation systems, regenerative kidney technology, trans-catheter cardiac valves and spinal implant device design. He has funded and started over 12 businesses in the Orthopedic, Spine and Neurological segments such as Biocraft Inc, Orthocraft Inc, Neurocraft Inc, Pharmacraft, Premier Medical Systems, and Diamond Orthopedics. Early in his career, he was one of the first agents for Danek a publicly traded spinal implant company which merged with Sofamor to become Sofamor-Danek and relisting on the NYSE. Sofamor-Danek was acquired by Medtronic in 1999 for $3.7 billion. Mr. Craft is a highly experienced entrepreneur who is continually exploring opportunities to multiply investments in medical businesses and technologies. Mr. Craft earned a B.S. degree in biomedical engineering from Mississippi State University, and is a Distinguished Fellow of the College of Engineering at Mississippi State University. Executive Compensation No executive officer has received any cash compensation for services rendered to us. No compensation of any kind, including finders, consulting or other similar fees, will be paid to any of our existing stockholders, including our directors, or any of their respective affiliates, prior to, or for any services they render in order to effectuate, the consummation of a business combination. However, such individuals will be reimbursed for any out-of-pocket expenses incurred in connection with activities on our behalf such as identifying potential target businesses and performing due diligence on suitable business combinations. There is no limit on the amount of these out-of-pocket expenses and there will be no review of the reasonableness of the expenses by anyone other than our board of directors and audit committee, which includes persons who may seek reimbursement, or a court of competent jurisdiction if such reimbursement is challenged. Director Independence The NYSE American stock exchange requires that a majority of our board must be composed of “independent directors,” which is defined generally as a person other than an officer or employee of the company or its subsidiaries or any other individual having a relationship, which, in the opinion of the company’s board of directors would interfere with the director’s exercise of independent judgment in carrying out the responsibilities of a director. Upon the effective date of the registration statement of which this prospectus forms a part, Lishan Aklog, Brian Cole and Doug Craft have become our independent directors. Our independent directors will have regularly scheduled meetings at which only independent directors are present. Any affiliated transactions will be on terms that our board believes are no less favorable to us than could be obtained from independent parties. Audit Committee Effective as of the date of this prospectus, we have established an audit committee of the board of directors, which will consist of Lishan Aklog, Brian Cole and Doug Craft, each of whom is an independent director under the NYSE American’s listing standards. Dr. Aklog is the Chairperson of the audit committee. The audit committee’s duties, which are specified in our Audit Committee Charter, include, but are not limited to: • reviewing and discussing with management and the independent auditor the annual audited financial statements, and recommending to the board whether the audited financial statements should be included in our Form 10-K; • discussing with management and the independent auditor significant financial reporting issues and judgments made in connection with the preparation of our financial statements; • discussing with management major risk assessment and risk management policies; • monitoring the independence of the independent auditor; 73 Table of Contents • verifying the rotation of the lead (or coordinating) audit partner having primary responsibility for the audit and the audit partner responsible for reviewing the audit as required by law; • reviewing and approving all related-party transactions; • inquiring and discussing with management our compliance with applicable laws and regulations; • pre-approving all audit services and permitted non-audit services to be performed by our independent auditor, including the fees and terms of the services to be performed; • appointing or replacing the independent auditor; • determining the compensation and oversight of the work of the independent auditor (including resolution of disagreements between management and the independent auditor regarding financial reporting) for the purpose of preparing or issuing an audit report or related work; • establishing procedures for the receipt, retention and treatment of complaints received by us regarding accounting, internal accounting controls or reports which raise material issues regarding our financial statements or accounting policies; and • approving reimbursement of expenses incurred by our management team in identifying potential target businesses. Financial Experts on Audit Committee Pursuant to NYSE American rules, the audit committee will at all times be composed exclusively of “independent directors” who are able to read and understand fundamental financial statements, including a company’s balance sheet, income statement and cash flow statement. In addition, we must certify to the NYSE American that the committee has, and will continue to have, at least one member who has past employment experience in finance or accounting, requisite professional certification in accounting, or other comparable experience or background that results in the individual’s financial sophistication. The board of directors has determined that Dr. Cole qualifies as an “audit committee financial expert,” as defined under rules and regulations of the NYSE American and the SEC. Nominating Committee Effective as of the date of this prospectus, we have established a nominating committee of the board of directors, which will consist of Lishan Aklog, Brian Cole and Doug Craft, each of whom is an independent director under the NYSE American’s listing standards. Dr. Cole is the Chairperson of the nominating committee. The nominating committee is responsible for overseeing the selection of persons to be nominated to serve on our board of directors. The nominating committee considers persons identified by its members, management, stockholders, investment bankers and others. Guidelines for Selecting Director Nominees The guidelines for selecting nominees, which are specified in the Nominating Committee Charter, generally provide that persons to be nominated: • should have demonstrated notable or significant achievements in business, education or public service; • should possess the requisite intelligence, education and experience to make a significant contribution to the board of directors and bring a range of skills, diverse perspectives and backgrounds to its deliberations; and • should have the highest ethical standards, a strong sense of professionalism and intense dedication to serving the interests of the stockholders. The nominating committee will consider a number of qualifications relating to management and leadership experience, background and integrity and professionalism in evaluating a person’s candidacy for membership on the board of directors. The nominating committee may require certain skills or attributes, such as financial or accounting 74 Table of Contents experience, to meet specific board needs that arise from time to time and will also consider the overall experience and makeup of its members to obtain a broad and diverse mix of board members

Holder Stats

1 0
% of Shares Held by All Insider 20.00%
% of Shares Held by Institutions 72.94%
% of Float Held by Institutions 91.17%
Number of Institutions Holding Shares 45

Mutual Fund Holders

Holder Shares Date Reported Value % Out
RiverNorth Opportunities Fd 32618 2021-07-30 323244 0.13
CrossingBridge Pre-Merger SPAC ETF 5510 2021-09-29 55044 0.02
First Tr Exchange Traded Fd-First Trust Multi-Strategy Fd 3405 2021-06-29 33709 0.01
First Tr Exchange Traded Fd-First Trust Alternative Opportunities Fd 1805 2021-06-29 17869 0.01

Institutional Holders

Reporting Date Hedge Fund Shares Held Market Value % of Portfolio Quarterly Change in Shares Ownership in Company
2021-11-15 Omni Partners US LLC 73,562 $730,000 0.0% -2.0% 0.292%
2021-11-15 Hunting Hill Global Capital LLC 79,179 $790,000 0.2% 0 0.315%
2021-11-12 Weiss Asset Management LP 1,511,800 $15,100,000 0.4% +9.0% 6.010%
2021-11-12 Cohanzick Management LLC 5,510 $55,000 0.0% 0 0.022%
2021-11-12 Crestline Management LP 29,533 $300,000 0.0% +16.8% 0.117%
2021-11-10 Goldman Sachs Group Inc. 518,797 $5,180,000 0.0% -0.5% 2.062%
2021-08-17 Weiss Multi Strategy Advisers LLC 25,431 $270,000 0.0% 0 0.101%
2021-08-17 Kohlberg Kravis Roberts & Co. L.P. 247,142 $2,450,000 0.0% +353.4% 0.982%
2021-08-16 CNH Partners LLC 60,000 $590,000 0.0% 0 0.239%
2021-08-16 Berkley W R Corp 953,914 $9,450,000 0.9% +105.1% 3.792%
2021-08-16 Goldman Sachs Group Inc. 521,150 $5,160,000 0.0% -0.5% 2.072%
2021-08-13 Qube Research & Technologies Ltd 14,140 $140,000 0.0% 0 0.056%
2021-08-12 State of Wisconsin Investment Board 217,399 $2,150,000 0.0% 0 0.864%
2021-08-12 JPMorgan Chase & Co. 253,432 $2,510,000 0.0% -11.7% 1.007%
2021-08-02 Dakota Wealth Management 58,550 $580,000 0.1% +43.9% 0.233%
2021-05-18 EJF Capital LLC 10,000 $98,000 0.0% 0 0.040%
2021-05-18 Berkley W R Corp 465,098 $4,570,000 0.5% +56.0% 1.849%
2021-05-18 Karpus Management Inc. 991,338 $9,740,000 0.3% 0 3.941%
2021-05-17 Kohlberg Kravis Roberts & Co. L.P. 54,509 $540,000 0.0% 0 0.217%
2021-05-17 Royal Bank of Canada 2,831 $28,000 0.0% 0 0.011%
2021-05-17 Omni Partners LLP 67,225 $660,000 0.0% 0 0.267%
2021-05-17 Goldman Sachs Group Inc. 523,650 $5,140,000 0.0% 0 2.082%
2021-05-14 GABELLI & Co INVESTMENT ADVISERS INC. 178,800 $1,840,000 0.2% 0 0.711%
2021-05-14 Gabelli Funds LLC 176,200 $1,820,000 0.0% 0 0.700%
2021-05-14 Weiss Asset Management LP 828,395 $8,140,000 0.2% 0 3.293%
2021-05-12 JPMorgan Chase & Co. 287,144 $2,820,000 0.0% 0 1.141%
2021-05-10 Dakota Wealth Management 40,700 $400,000 0.1% 0 0.162%
2021-05-07 Alberta Investment Management Corp 16,427 $160,000 0.0% 0 0.065%
2021-04-28 Mizuho Securities USA LLC 785,000 $7,650,000 0.7% 0 3.121%

SEC Filings

Form Type Form Description Filing Date Document Link
10-Q QUARTERLY REPORT 2021-11-17
8-K CURRENT REPORT 2021-11-16
10-Q QUARTERLY REPORT 2021-08-16
10-Q QUARTERLY REPORT 2021-07-02
10-K/A AMENDMENT NO. 1 TO FORM 10-K 2021-07-02
8-K CURRENT REPORT 2021-07-02
8-K CURRENT REPORT 2021-05-28
3 2021-05-12
8-K CURRENT REPORT 2021-04-30
8-K CURRENT REPORT 2021-04-26
10-K ANNUAL REPORT 2021-04-09
4/A 2021-04-08
4/A 2021-04-08
SC 13G 2021-02-12
SC 13G SCHEDULE 13G 2021-02-12
SC 13G FORM SC 13G 2021-02-11
SC 13G FORM SC 13G 2021-02-10
10-Q QUARTERLY REPORT 2021-02-05
8-K CURRENT REPORT 2021-02-02
8-K CURRENT REPORT 2021-01-04
4 2021-01-04
4 2021-01-04
3 2021-01-04
4 2020-12-31
4 2020-12-31
4 2020-12-31
3 2020-12-31
8-K FORM 8-K 2020-12-29
4 2020-12-28
4 2020-12-28
4 2020-12-28
4 2020-12-28
3 2020-12-28
424B4 2020-12-28
EFFECT 2020-12-22
CORRESP 2020-12-21
CORRESP 2020-12-21
CORRESP 2020-12-18
UPLOAD 2020-12-18
DRS 2020-09-10